MustGrow Closes $3.7 Million Non-Brokered LIFE Offering

About this update from Mustgrow Biologics Corp.

Saskatoon, Saskatchewan--(Newsfile Corp. - June 19, 2026) - MustGrow Biologics Corp. (TSXV: MGRO) (OTCQB: MGROF) (FSE: 0C0) (the "Company" or "MustGrow"), is pleased to announce the closing of its previously announced non-brokered private placement of 7,481,541 units of the Company (each, a "Unit") at a price of $0.50 per Unit for gross proceeds of approximately $3,741,000 (the "LIFE Offering"). Each Unit consists of (i) one common share of the Company (each, a "Common Share") and (ii) one common share purchase warrant (each, a "Warrant"). Each whole Warrant will be exercisable for a period of 60 months from the date of closing and will entitle the holder thereof to purchase one additional Common Share (each, a "Warrant Share") at an exercise price of $0.70 per Warrant Share. The Company intends to use the net proceeds raised from the LIFE Offering for inventory production for its mustard-derived organic biofertility product TerraSanteTM and working capital and general corporate purposes. The Units sold pursuant to the LIFE Offering were offered in Canada pursuant to the listed issuer financing exemption from the prospectus requirement available under Part 5A of National Instrument 45-106 - Prospectus Exemptions as modified by Coordinated Blanket Order 45-935 Exemptions from Certain Conditions of the Listed Issuer Financing Exemption, in the United States pursuant to available exemptions from the registration requirements of the United States Securities Act of 1933 (the "1933 Act"), as amended, and in certain other jurisdictions outside of Canada and the United States provided that no prospectus filing or comparable obligation arises in such other jurisdiction. Subject to the rules and policies of the TSX Venture Exchange (the "TSXV"), the securities issuable from the sale of Units to Canadian resident subscribers will not be subject to a hold period under applicable Canadian securities laws. The LIFE Offering remains subject to final approval of the TSXV. As consideration for services, certain eligible finders received: (i) an aggregate cash fee equal to $110,865, being 6.0% of the gross proceeds of the LIFE Offering from investors introduced to the Company by such finders; and (ii) 221,730 non-transferable Common Share purchase warrants (the "Finder's Warr...

View stock analysis, news, and events for Mustgrow Biologics Corp.